Science

ASSOCIATED PRESS  by Maria Cheng                                                                          Jan. 9, 2015
LONDON --The World Health Organizationsays the two leading Ebola vaccines appear safe and will soon be tested in healthy volunteers in West Africa.

After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines ? one made by GlaxoSmithKline and the other licensed by Merck and NewLink ? have "an acceptable safety profile."

In a press briefing on Friday, Dr. Marie-Paule Kieny, who heads WHO's Ebola vaccine efforts, said "the cupboard (for Ebola vaccines) is filling up rapidly."

She said further trials in healthy people in West Africa, including health workers, are scheduled to start soon. Kieny added several other vaccines were being developed in the U.S., Russia and elsewhere.

Read complete story.
http://abcnews.go.com/Health/wireStory/leading-ebola-vaccines-safe-tests-starting-28107527

NEW YORK TIMES  by Donald G. McNeil, Jr.                                                     Jan. 1, 2015

Medical experts seeking to stem the Ebola epidemic are sharply divided over whether most patients in West Africa should, or can, be given intravenous hydration, a therapy that is standard in developed countries. Some argue that more aggressive treatment with IV fluids is medically possible and a moral obligation. But others counsel caution, saying that pushing too hard would put overworked doctors and nurses in danger and that the treatment, if given carelessly, could even kill patients.

A nurse gave an Ebola patient intravenous fluids at the Red Cross treatment center in Kenema, Sierra Leone, in November. Credit Francisco Leong/Agence France-Presse — Getty Images

OXFORD UNIVERSITY PRESS                                                                                  Dec, 10, 2014

In an editorial published online today in the International Journal of Epidemiology, experts from the Departments of Psychiatry and Epidemiology at Columbia University, New York, are calling for survivors of the Ebola epidemic to be mobilised in a bid to hasten containment of the disease.

We already know that the current Ebola outbreak is unique in its magnitude and for its dispersion in dense, mobile populations. Physicians and nurses face high mortality, and foreign aid in the form of medical supplies and staff continues to be unequal to the scope of the problem. With a case recovery rate of around 30% at the present time in West Africa, survivors already number in the thousands.

REPORTS Of RESEARCH ON TWO METHODS OF RAPID TESTING FOR EBOLA

(Two items, scroll down)

MEDICAL PRESS                                                                                     Dec. 8, 2014

Rutgers researcher David Alland, working with the California biotechnology company Cepheid, has received a grant of nearly $640,000 from the National Institutes of Health to develop a rapid test to diagnose Ebola as well as other viruses that can cause symptoms similar to Ebola.

Researchers will adapt this cartridge, now used worldwide for tuberculosis screenings, to collect and test samples from potential Ebola patients. Credit: John Emerson

Alland, a professor of medicine and associate dean for clinical research at Rutgers New Jersey Medical School and the principal investigator of the project, says health workers would be able to take the test to small villages and other remote locations where the spread of Ebola has been especially rampant and diagnose patients where they live...